scholarly journals A novel split mode TFBAR device for quantitative measurements of prostate specific antigen in a small sample of whole blood

Nanoscale ◽  
2020 ◽  
Vol 12 (17) ◽  
pp. 9647-9652
Author(s):  
Ewelina Wajs ◽  
Girish Rughoobur ◽  
Keith Burling ◽  
Anne George ◽  
Andrew J. Flewitt ◽  
...  

TFBAR technology demonstrates a cost-effective means for point-of-care diagnostics and monitoring of PSA.

2001 ◽  
Vol 47 (4) ◽  
pp. 703-711 ◽  
Author(s):  
Timo Piironen ◽  
Martti Nurmi ◽  
Kerttu Irjala ◽  
Olli Heinonen ◽  
Hans Lilja ◽  
...  

Abstract Background: The purpose of this study was to validate the use of whole-blood samples in the determination of circulating forms of prostate-specific antigen (PSA). Methods: Blood samples of hospitalized prostate cancer and benign prostatic hyperplasia patients were collected and processed to generate whole-blood and serum samples. Three different rapid two-site immunoassays were developed to measure the concentrations of total PSA (PSA-T), free PSA (PSA-F), and PSA-α1-antichymotrypsin complex (PSA-ACT) to detect in vitro changes in whole-blood samples immediately after venipuncture. The possible influence of muscle movement on the release of PSA from prostate gland was studied in healthy men by measuring the rapid in vitro whole-blood kinetics of PSA forms before and after 15 min of physical exercise on a stationary bicycle. Results: Rapid PSA-T, PSA-F, and PSA-ACT assays were designed using a 10-min sample incubation. No significant changes were detected in the concentrations of PSA-T, PSA-F, and PSA-ACT from the earliest time point of 12–16 min compared with measurements performed up to 4 h after venipuncture. Physical exercise did not influence the concentrations of the circulating forms of PSA. Hematocrit-corrected whole-blood values of PSA-T and PSA-F forms were comparable to the respective serum values. Calculation of the percentage of PSA-F (PSA F/T ratio × 100) was similar irrespective of the sample format used, i.e., whole blood or serum. Conclusions: We found that immunodetectable PSA forms are likely at steady state immediately after venipuncture, thus enabling the use of anticoagulated whole-blood samples in near-patient settings for point-of-care testing, whereas determinations of PSA (e.g., PSA-T, PSA-F, or PSA-ACT) performed within the time frame of the office visit would provide results equivalent to conventional analyses performed in serum.


Lab on a Chip ◽  
2014 ◽  
Vol 14 (16) ◽  
pp. 2918-2928 ◽  
Author(s):  
Ana I. Barbosa ◽  
Ana P. Castanheira ◽  
Alexander D. Edwards ◽  
Nuno M. Reis

A “lab-in-a-briefcase” for point-of-care PSA screening that can perform 80 measurements of PSA levels in human blood in 15 minutes.


2015 ◽  
Vol 69 (1) ◽  
Author(s):  
Pawan Jolly ◽  
Nello Formisano ◽  
Pedro Estrela

AbstractThe use of aptamers in biosensing has attracted considerable attention as an alternative to antibodies because of their unique properties such as long-term stability, cost-effectiveness and adjustability to various applications. Among cancers, the early diagnosis of prostate cancer (PCa) is one of the greatest concerns for ageing men worldwide. One of the most commonly used biomarkers for PCa is prostate-specific antigen (PSA), which can be found in elevated levels in patients with cancer. This review presents the gradual transition of research from antibody-based to aptamerbased biosensors, specifically for PSA. A brief description on aptamer-based biosensing for other PCa biomarkers is also presented. Special attention is given to electrochemical methods as analytical techniques for the development of simple, sensitive and cost-effective biosensors. The review also focuses on the different surface chemistries exploited for fabrication and their applications in clinical samples. The use of aptamers represents a promising tool for the development of point-ofcare biosensors for the early detection of prostate cancer. In view of the unmatched upper hand of aptamers, future prospects are also discussed, not only in the point-of-care format but also in other novel applications.


2002 ◽  
Vol 48 (8) ◽  
pp. 1272-1278 ◽  
Author(s):  
Barbara R Grzeda ◽  
Tuan Le Bui ◽  
Cheryl N Warner ◽  
Tracy L Pirucki ◽  
Lisa M Dewey ◽  
...  

Abstract Background: Prostate-specific antigen (PSA) is widely used in the detection and monitoring of prostate cancer. We developed a system for the self-collection and transport of capillary whole blood for PSA analysis, with the goal of reducing phlebotomy visits and, thus, increasing the access and utilization of PSA in prostate cancer screening and monitoring. Methods: The blood collection device [BIOSAFE Blood Transport System (BTSTM)] collects 70 μL of blood through a heparin-coated material into 200 μL of stabilizing solution. The diluted whole blood is used for measurement of PSA by a modified version of the Hybritech® Tandem-MP PSA Assay. Results were compared for matched samples of professionally and self-collected BTS blood and for matched BTS samples sera from blood collected by venipuncture. Imprecision for the whole-blood PSA measurement was estimated from analysis of whole-blood controls in duplicate, twice per day, over 20 days. Results: BTS samples (n = 140) collected by a qualified healthcare professional compared with serum samples yielded the regression equation: y =1.02x + 0.04 (Sy|x = 0.35; r = 0.99). Comparison of the results for samples (n = 128) collected by the patient without professional assistance with serum samples yielded: y = 1.08x + 0.02 (Sy|x = 0.31; r = 0.99). The between-run CVs at 0.069, 0.53, 2.9, and 10.7 μg/L were 21%, 6.0%, 3.5%, and 3.8%, respectively. PSA was stable in BTS samples stored for 21 days at 18–24 °C and for 7 days at 37 °C. Conclusion: The BIOSAFE BTS system allows accurate and convenient measurement of circulating PSA by a precise method for diluted whole blood.


1996 ◽  
Vol 42 (4) ◽  
pp. 536-544 ◽  
Author(s):  
B R Hoffman ◽  
H Yu ◽  
E P Diamandis

Abstract We report the measure of prostate-specific antigen (PSA) from extracts of blood dried on filter paper. Five 3-mm (diameter) paper discs containing approximately 25 microL of dried whole blood were punched from the filter paper and extracted with 500 microL of buffer. Recovery of PSA was > 92%. Imprecision of the filter paper procedure was <10% when corresponding whole-blood concentrations were >0.35 micrograms/L. PSA recovery was unaffected whether blood was applied to the filter as one 85-microL aliquots, two 43-microL aliquots, or three 28-microL aliquots. PSA is contained in the plasma fraction. Variation in hematocrit from 0.61 to 0.31 caused <+/-10% change in filter paper PSA. Regression analysis showed: filter paper PSA = 0.86 whole-blood PSA - 0.02; Sy/x = 0.44. Men (153) without prostate cancer gave a 95th percentile of 4.8 micrograms /L. PSA in filter paper dried blood was stable for >1 month at -20 to 37 degrees C and showed no loss of recovery after being mailed to a hot climate. We conclude that the filter paper procedure can reliably distinguish normal from increased concentrations of PSA and that it could facilitate screening to detect occult prostate cancer in large-scale mail-in programs to centralized laboratories.


1995 ◽  
Author(s):  
Grenville Robinson ◽  
Timothy Bacarese-Hamilton ◽  
Paul M. O'Neill ◽  
Janys E. Fletcher ◽  
Phelim B. Daniels ◽  
...  

BMC Urology ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Steffen Rausch ◽  
Joerg Hennenlotter ◽  
Josef Wiesenreiter ◽  
Andrea Hohneder ◽  
Julian Heinkele ◽  
...  

2009 ◽  
Vol 81 (15) ◽  
pp. 6030-6037 ◽  
Author(s):  
Andreas Lenshof ◽  
Asilah Ahmad-Tajudin ◽  
Kerstin Järås ◽  
Ann-Margret Swärd-Nilsson ◽  
Lena Åberg ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document